Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 65% of modeled bridge. Risks: Bed Count. Risk-adjusted uplift: $19.7M (vs $30.2M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $11.5M | $11.5M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $11.0M | $316K | $11.4M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $1.8M | $5.2M | $7.0M | $22.0M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $367K | $367K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 29.5% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $2.9M | $5.7M | $8.6M | $11.5M | $11.5M | $11.5M | $11.5M |
| Denial Rate Reduction | $0 | $2.8M | $5.7M | $8.5M | $11.4M | $11.4M | $11.4M | $11.4M |
| A/R Days Reduction | $0 | $2.3M | $4.7M | $7.0M | $7.0M | $7.0M | $7.0M | $7.0M |
| Clean Claim Rate | $0 | $184K | $367K | $367K | $367K | $367K | $367K | $367K |
| Cumulative | $0 | $8.2M | $16.4M | $24.5M | $30.2M | $30.2M | $30.2M | $30.2M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $30.2M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 80% / 19.1x | 85% / 21.6x | 89% / 24.1x | 91% / 25.4x | 93% / 26.6x |
| 9.0x | 76% / 16.6x | 80% / 18.9x | 84% / 21.1x | 86% / 22.2x | 88% / 23.3x |
| 10.0x | 71% / 14.7x | 76% / 16.6x | 80% / 18.6x | 81% / 19.6x | 83% / 20.6x |
| 11.0x | 67% / 13.0x | 72% / 14.8x | 76% / 16.6x | 77% / 17.6x | 79% / 18.5x |
| 12.0x | 63% / 11.7x | 68% / 13.3x | 72% / 15.0x | 74% / 15.8x | 76% / 16.6x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 55% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 2.9x, adding 5.5 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $15.9M | — | $15.9M | 2.8% |
| Year 1 | $16.3M | +$20.1M | $36.5M | 6.4% |
| Year 2 | $16.8M | +$30.2M | $47.0M | 8.2% |
| Year 3 | $17.3M | +$30.2M | $47.5M | 8.3% |
| Year 4 | $17.9M | +$30.2M | $48.0M | 8.4% |
| Year 5 | $18.4M | +$30.2M | $48.6M | 8.5% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $5.7M | $8.6M | $11.5M | $13.8M |
| Denial Rate Reductio | $5.7M | $8.5M | $11.4M | $13.6M |
| A/R Days Reduction | $3.5M | $5.2M | $7.0M | $8.4M |
| Clean Claim Rate | $184K | $275K | $367K | $441K |
| Total | $15.1M | $22.6M | $30.2M | $36.2M |
Peer Context — Where This Hospital Sits
Key metrics vs 30 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 2.8% | -12.2% | -2.6% | 4.7% | P67 |
| Net-to-Gross | 27.7% | 22.7% | 26.9% | 29.5% | P53 |
| Occupancy | 52.1% | 52.1% | 66.1% | 75.5% | P23 |
| Rev/Bed | $1.5M | $1.1M | $1.5M | $1.9M | P47 |
| Exp/Bed | $1.4M | $1.1M | $1.5M | $1.8M | P37 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.